7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sphingosine kinases negatively regulate the expression of matrix metalloproteases ( MMP1 and MMP3) and their inhibitor TIMP3 genes via sphingosine 1‐phosphate in extravillous trophoblasts

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Extracellular matrix remodeling is essential for extravillous trophoblast (EVT) cell migration and invasion during placental development and regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteases (TIMPs). Sphingosine kinases (SPHK1 and SPHK2) synthesize sphingosine‐1‐phosphate (S1P), which works either intracellularly or extracellularly via its receptors S1PR1‐5 in an autocrine or paracrine manner. The role of SPHKs/S1P in regulating the expression of MMPs and TIMPs in EVT is mostly unknown and forms the primary objective of the study.

          Methods

          HTR‐8/SVneo cells were used as a model of EVT. To inhibit the expression of SPHKs, cells were treated with specific inhibitors, SK1‐I and SKI‐II, or gene‐specific siRNAs. The expressions of MMPs and TIMPs were estimated by qPCR.

          Results

          We demonstrated that SPHK1, MMP1‐3, and TIMP1‐3 were highly expressed in HTR‐8/SVneo cells. We found that treatment of cells with SK1‐I, SKI‐II, and knockdown of SPHK1 or SPHK2 increased the expression of MMP1, MMP3, and TIMP3. The addition of extracellular S1P inhibits the upregulation of MMPs and TIMPs in treated cells.

          Conclusions

          SPHKs negatively regulate the expression of MMP1, MMP3, and TIMP3. The level of intracellular S1P acts as a negative feedback switch for MMP1, MMP3, and TIMP3 expression in EVT cells.

          Abstract

          The levels of intracellular S1P act as a controlling switch for MMP1, MMP3, and TIMP3 expression in EVT cells suggesting a new role of intracellular S1P in ECM remodeling.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Remodelling the extracellular matrix in development and disease.

          The extracellular matrix (ECM) is a highly dynamic structure that is present in all tissues and continuously undergoes controlled remodelling. This process involves quantitative and qualitative changes in the ECM, mediated by specific enzymes that are responsible for ECM degradation, such as metalloproteinases. The ECM interacts with cells to regulate diverse functions, including proliferation, migration and differentiation. ECM remodelling is crucial for regulating the morphogenesis of the intestine and lungs, as well as of the mammary and submandibular glands. Dysregulation of ECM composition, structure, stiffness and abundance contributes to several pathological conditions, such as fibrosis and invasive cancer. A better understanding of how the ECM regulates organ structure and function and of how ECM remodelling affects disease progression will contribute to the development of new therapeutics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Sphingolipid metabolism in cancer signalling and therapy

            Sphingolipids, including the two central bioactive lipids ceramide and sphingosine-1-phosphate (S1P), have opposing roles in regulating cancer cell death and survival, respectively, and there have been exciting developments in understanding how sphingolipid metabolism and signalling regulate these processes in response to anticancer therapy. Recent studies have provided mechanistic details of the roles of sphingolipids and their downstream targets in the regulation of tumour growth and response to chemotherapy, radiotherapy and/or immunotherapy using innovative molecular, genetic and pharmacological tools to target sphingolipid signalling nodes in cancer cells. For example, structure-function-based studies have provided innovative opportunities to develop mechanism-based anticancer therapeutic strategies to restore anti-proliferative ceramide signalling and/or inhibit pro-survival S1P-S1P receptor (S1PR) signalling. This Review summarizes how ceramide-induced cellular stress mediates cancer cell death through various mechanisms involving the induction of apoptosis, necroptosis and/or mitophagy. Moreover, the metabolism of ceramide for S1P biosynthesis, which is mediated by sphingosine kinase 1 and 2, and its role in influencing cancer cell growth, drug resistance and tumour metastasis through S1PR-dependent or receptor-independent signalling are highlighted. Finally, studies targeting enzymes involved in sphingolipid metabolism and/or signalling and their clinical implications for improving cancer therapeutics are also presented.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sphingosine-1-phosphate signaling and its role in disease.

              The bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) is now recognized as a critical regulator of many physiological and pathophysiological processes, including cancer, atherosclerosis, diabetes and osteoporosis. S1P is produced in cells by two sphingosine kinase isoenzymes, SphK1 and SphK2. Many cells secrete S1P, which can then act in an autocrine or paracrine manner. Most of the known actions of S1P are mediated by a family of five specific G protein-coupled receptors. More recently, it was shown that S1P also has important intracellular targets involved in inflammation, cancer and Alzheimer's disease. This suggests that S1P actions are much more complex than previously thought, with important ramifications for development of therapeutics. This review highlights recent advances in our understanding of the mechanisms of action of S1P and its roles in disease. Copyright © 2011 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                pankaj_bio@curaj.ac.in
                Journal
                Reprod Med Biol
                Reprod Med Biol
                10.1111/(ISSN)1447-0578
                RMB2
                Reproductive Medicine and Biology
                John Wiley and Sons Inc. (Hoboken )
                1445-5781
                1447-0578
                22 March 2021
                July 2021
                : 20
                : 3 ( doiID: 10.1111/rmb2.v20.3 )
                : 267-276
                Affiliations
                [ 1 ] Department of Biotechnology School of Life Sciences Central University of Rajasthan Ajmer India
                [ 2 ] Comprehensive Cancer Center Mainfranken Translational Oncology University Hospital of Würzburg Würzburg Germany
                [ 3 ] Department of Obstetrics & Gynecology J. L. N. Medical College Ajmer India
                Author notes
                [*] [* ] Correspondence

                Pankaj Goyal, Department of Biotechnology, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Rajasthan, India.

                Email: pankaj_bio@ 123456curaj.ac.in

                Author information
                https://orcid.org/0000-0001-8080-1745
                https://orcid.org/0000-0003-0870-9578
                https://orcid.org/0000-0003-0322-3907
                https://orcid.org/0000-0002-9916-654X
                Article
                RMB212379
                10.1002/rmb2.12379
                8254167
                34262394
                aab08614-4179-4499-b4b2-9f21df041cb8
                © 2021 The Authors. Reproductive Medicine and Biology published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 02 February 2021
                : 23 September 2020
                : 04 March 2021
                Page count
                Figures: 7, Tables: 0, Pages: 10, Words: 5359
                Funding
                Funded by: Department of Biotechnology, Ministry of Science and Technology , open-funder-registry 10.13039/501100001407;
                Award ID: BT/PR22450/MED/97/351/2016
                Funded by: Science and Engineering Research Board , open-funder-registry 10.13039/501100001843;
                Award ID: PDF/2016/000292
                Award ID: PDF/2016/003711
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                July 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.4 mode:remove_FC converted:03.07.2021

                extravillous trophoblast,matrix metalloproteinases,sphingosine 1‐phosphate,sphingosine kinase,tissue inhibitors of metalloproteases

                Comments

                Comment on this article